Jazz Pharmaceuticals: The Concept Bet, at a Whole New Level

The press around the size of Jazz Pharmaceuticals' $250 million private financing has obscured the whole point: the company and the financing represent a fundamentally different business model for biopharmaceutical investing and companies: betting on product concepts--not products and not technology.